// App-Quantinova.ai

: Intra-individual dose escalation of abiraterone (ABI) according to its plasma exposure in patients (pts) with progressive metastatic castration-resistant prostate cancer (mRCPC): Results of the OPTIMABI trial.

Researchers

Presenter

  • Jerome Alexandre

Principal Investigators

  • Luca Campedel

  • Lisa Golmard

  • Sylvain Ladoire

  • Ahmed Khalil

  • Denis Maillet

  • Christophe Tournigand

  • Françoise Goirand

  • Jerome Guitton

  • Charles Dariane

  • Florence Joly

  • Evanguelos Xylinas

  • Jean Louis Golmard

  • Hendy Abdoul

  • Nihel Khoudour

  • Alicja Puskiel

  • Edith Carton

  • Olivier Huillard

  • Benoit Blanchet

Medical Centers

  • Sorbonne Université, APHP, hôpital Tenon, Paris, France

  • Université Paris Cité, AP-HP, Unité de recherche clinique, Cochin, Paris, France

  • Department of Medical Oncology, Hôpital Cochin, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, France

  • Paris, France

  • Laboratoire de Pharmacologie et Toxicologie, CHU Dijon, Dijon, France

  • Department of Medical Oncology, Henri Mondor Hospital, AP-HP, Paris-East Créteil University, INSERM, IMRB, Créteil, France

  • Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Lyon-Sud Hospital, Lyon, France

  • Université Paris Cité, AP-HP, Cochin-Port Royal, CARPEM, Paris, France

  • Centre Francois Baclesse, Caen, France

  • Dpt of genetic, Institut Curie, Paris, France

  • Saint Gregoire, Saint Gregoire, France

  • Bichat-Claude Bernard Hospital, Assistance Publique–Hôpitaux de Paris, Université Paris Cité, Paris, France

  • Université Paris Cité, AP-HP, Hôpital Européen Georges Pompidou, Urologie, Paris, France

  • Center Georges-Francois Leclerc, Dijon, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Apoptotic body index

Drug/Treatment

  • CB-7598

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT03458247

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved